David Dai
Stock Analyst at UBS
(0.41)
# 4,109
Out of 4,832 analysts
21
Total ratings
21.05%
Success rate
-30.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.19 | +233.80% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $71.19 | +40.47% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $5.73 | +144.33% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $27.70 | -13.36% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $97.57 | -9.81% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.16 | +825.93% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $9.59 | +264.96% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $40.40 | +78.22% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $22.62 | +205.04% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $17.10 | +192.40% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.71 | +897.07% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $24.17 | +148.24% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $9.28 | +298.71% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.64 | +4,241.76% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $10.90 | +266.97% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.55 | +2,480.65% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.87 | +2,573.80% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $35.73 | +45.54% | 1 | Mar 17, 2020 |
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.19
Upside: +233.80%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $71.19
Upside: +40.47%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $5.73
Upside: +144.33%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $27.70
Upside: -13.36%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $97.57
Upside: -9.81%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.16
Upside: +825.93%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $9.59
Upside: +264.96%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $40.40
Upside: +78.22%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $22.62
Upside: +205.04%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $17.10
Upside: +192.40%
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $1.71
Upside: +897.07%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $24.17
Upside: +148.24%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $9.28
Upside: +298.71%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.64
Upside: +4,241.76%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $10.90
Upside: +266.97%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.55
Upside: +2,480.65%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.87
Upside: +2,573.80%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $35.73
Upside: +45.54%